Time and Motion Study to Quantify Time for Tysabri (Natalizumab) Intravenous Versus Subcutaneous to Treat Relapsing-Remitting Multiple Sclerosis in France, Spain, and the United Kingdom

E De Cock; Khalil Jomaa; Jyothi Menon; Carlos Ríos; Rona Lyn Esquejo-Leon; Peter Oliver-Smith

doi:10.1007/s40120-026-00888-1

February 14, 2026Neurology and TherapyOpen Access

Time and Motion Study to Quantify Time for Tysabri (Natalizumab) Intravenous Versus Subcutaneous to Treat Relapsing-Remitting Multiple Sclerosis in France, Spain, and the United Kingdom

View Full Paper

Ask AI

Bookmark

Share

Key Points

To compare the time and operational efficiency of subcutaneous versus intravenous administration of natalizumab for treating relapsing-remitting multiple sclerosis.
Conducted a time and motion study across France, Spain, and the United Kingdom.
Compared active healthcare provider time and patient chair time for both administration routes.
Surveyed healthcare providers' satisfaction and preference regarding administration methods.
Subcutaneous administration significantly reduced active healthcare provider time.
Patient chair time was also lower for subcutaneous compared to intravenous administration.
Healthcare providers preferred subcutaneous administration, indicating higher satisfaction.

Implication

Study reveals improved healthcare efficiency using subcutaneous natalizumab in multiple sclerosis treatment.

Abstract

Natalizumab SC offers substantial savings in active HCP time and patient chair time compared with natalizumab IV. HCPs reported higher satisfaction and a preference for natalizumab SC. The HCP time and infusion chair capacity made available with natalizumab SC could be reallocated to other patient-care activities or used to treat additional patients, thereby improving overall healthcare efficiency.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Cock et al. (2026) studied this question.

synapsesocial.com/papers/699405254e9c9e835dfd5f74 https://doi.org/10.1007/s40120-026-00888-1

View Full Paper

Ask AI

Bookmark

Share

Time and Motion Study to Quantify Time for Tysabri (Natalizumab) Intravenous Versus Subcutaneous to Treat Relapsing-Remitting Multiple Sclerosis in France, Spain, and the United Kingdom

Key Points

Implication

Abstract

Discussion

Cite This Study

Time and Motion Study to Quantify Time for Tysabri (Natalizumab) Intravenous Versus Subcutaneous to Treat Relapsing-Remitting Multiple Sclerosis in France, Spain, and the United Kingdom

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Neurology and Therapy

Keep reading

More related papers

More from Neurology and Therapy